Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Medy-Tox Inc. (086900.KQ)
Cheongju, KR
Medy-Tox Inc., a biopharmaceutical company established in 2000 and headquartered in Cheongju, South Korea, develops and distributes a diverse array of medical products. Its offerings include several botulinum toxin treatments: Neuronox, a lyophilized injectable powder, which is utilized for treating foot deformities caused by spasticity in children with cerebral palsy; INNOTOX, a transparent liquid injectable solution aimed at the temporary improvement of moderate to severe glabellar wrinkles; and Coretox, another freeze-dried injectable powder, also formulated for temporarily reducing moderate to severe frown lines. The company also manufactures hyaluronic acid-based dermal fillers, such as Neuramis and Potenfill, which function as tissue-recovering biomaterials. Beyond injectables, Medy-Tox provides various medical devices, including ComfortDual and Recell Ice, designed for tissue coagulation using high-frequency current; Neurajet Plus, an assisting tool for administering other pharmaceuticals; Carewave, which employs low-intensity electromagnetic shockwaves to address erectile dysfunction; and Careveam, an ultraviolet light device for managing skin ailments. Furthermore, the company offers Neurakin cream, a topical treatment for a range of dermatological conditions including acute and chronic eczema, contact and atopic dermatitis, rosacea and perioral dermatitis, herpes zoster, and acne vulgaris. Medy-Tox's products are exported to approximately 60 countries worldwide, with key markets encompassing Japan, Thailand, and Brazil. The company is also collaborating with Dyadic International, Inc. to develop vaccines targeting COVID-19 variants.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -5.03% | -0.59% | +0.00% | -23.56% | -18.61% | -16.75% | -36.47% | -58.74% | -36.74% | -72.68% | +731.62% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 2 | 0 |
| Sell | 1 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+8.2% ★ Q1'26: -5.1% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-10.8% Q1'26: +97.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+21.1% ★ Q1'26: +11.5% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+6.7% ★ Q1'26: +12.1% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+3.5% ★ Q1'26: +5.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+8.5% Q1'26: +5.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×2.09× Q1'26: 2.60× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 3 Rev. Ana. 3 EPS Ana. |
Dec 2027 4 Rev. Ana. 4 EPS Ana. |
Dec 2028 2 Rev. Ana. 3 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
88.51B
est: 88.27B (+0.3%)
|
133.26B
est: 130.50B (+2.1%)
|
181.24B
est: 180.42B (+0.5%)
|
205.44B
est: 213.81B (-3.9%)
|
205.90B
est: 204.72B (+0.6%)
|
140.83B
est: 141.20B (-0.3%)
|
184.87B
est: 178.41B (+3.6%)
|
195.10B
est: 191.75B (+1.7%)
|
221.12B
est: 220.22B (+0.4%)
|
228.62B
est: 233.50B (-2.1%)
|
247.29B
est: 249.51B (-0.9%)
|
269.84B
266.20B – 272.40B
+8.2% YoY
|
285.02B
261.20B – 333.80B
+5.6% YoY
|
313.29B
297.46B – 343.02B
+9.9% YoY
|
| EBITDA |
55.97B
est: 24.47B (+128.7%)
|
81.42B
est: 36.18B (+125.1%)
|
95.23B
est: 50.01B (+90.4%)
|
101.53B
est: 59.27B (+71.3%)
|
43.45B
est: 56.75B (-23.4%)
|
-16.93B
est: 39.14B (-143.3%)
|
152.76B
est: 49.45B (+208.9%)
|
70.37B
est: 53.15B (+32.4%)
|
32.70B
est: 61.05B (-46.4%)
|
39.18B
est: 77.26B (-49.3%)
|
36.62B
est: 82.55B (-55.6%)
|
89.28B
88.08B – 90.13B
+8.2% YoY
|
94.30B
86.42B – 110.44B
+5.6% YoY
|
103.66B
98.42B – 113.49B
+9.9% YoY
|
| EBIT |
52.13B
est: 16.24B (+221.0%)
|
76.67B
est: 24.01B (+219.3%)
|
87.31B
est: 33.19B (+163.0%)
|
86.97B
est: 39.34B (+121.1%)
|
24.86B
est: 37.66B (-34.0%)
|
-35.53B
est: 25.98B (-236.8%)
|
134.50B
est: 32.82B (+309.8%)
|
55.06B
est: 35.28B (+56.1%)
|
17.32B
est: 40.52B (-57.2%)
|
19.23B
est: 57.88B (-66.8%)
|
16.62B
est: 61.85B (-73.1%)
|
66.89B
65.98B – 67.52B
+8.2% YoY
|
70.65B
64.74B – 82.74B
+5.6% YoY
|
77.66B
73.73B – 85.03B
+9.9% YoY
|
| Net Income |
42.29B
est: 39.78B (+6.3%)
|
59.23B
est: 56.29B (+5.2%)
|
70.11B
est: 67.91B (+3.2%)
|
69.96B
est: 71.63B (-2.3%)
|
26.21B
est: 30.51B (-14.1%)
|
-29.58B
est: -22.30B (-32.6%)
|
94.15B
est: 91.22B (+3.2%)
|
37.01B
est: 41.84B (-11.5%)
|
9.76B
est: 12.96B (-24.7%)
|
16.95B
est: 18.49B (-8.3%)
|
16.59B
est: 21.69B (-23.5%)
|
28.03B
23.78B – 31.04B
+29.2% YoY
|
43.80B
31.99B – 51.50B
+56.3% YoY
|
54.34B
50.77B – 61.04B
+24.1% YoY
|
| SGA |
5.04B
est: 27.39B (-81.6%)
|
8.49B
est: 40.50B (-79.0%)
|
14.78B
est: 55.99B (-73.6%)
|
18.89B
est: 66.36B (-71.5%)
|
47.11B
est: 63.53B (-25.8%)
|
73.96B
est: 43.82B (+68.8%)
|
44.45B
est: 55.37B (-19.7%)
|
52.55B
est: 59.51B (-11.7%)
|
61.44B
est: 68.34B (-10.1%)
|
54.61B
est: 59.73B (-8.6%)
|
62.42B
est: 63.82B (-2.2%)
|
69.02B
68.09B – 69.68B
+8.2% YoY
|
72.90B
66.81B – 85.38B
+5.6% YoY
|
80.13B
76.09B – 87.74B
+9.9% YoY
|
| EPS |
6,453.81
est: 5,915.72 (+9.1%)
|
9,064.60
est: 8,372.10 (+8.3%)
|
10,793.00
est: 10,099.20 (+6.9%)
|
11,112.00
est: 10,652.31 (+4.3%)
|
4,050.83
est: 4,537.98 (-10.7%)
|
-4,609.84
est: -3,316.03 (-39.0%)
|
14,587.00
est: 13,566.00 (+7.5%)
|
5,491.68
est: 6,221.90 (-11.7%)
|
1,311.00
est: 1,926.92 (-32.0%)
|
2,377.00
est: 2,533.50 (-6.2%)
|
2,119.41
est: 2,972.17 (-28.7%)
|
3,840.23
3,258.00 – 4,253.70
+29.2% YoY
|
6,001.65
4,382.77 – 7,056.81
+56.3% YoY
|
7,445.79
6,956.81 – 8,364.24
+24.1% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-11 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-08 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-07 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-06 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-04 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-30 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-29 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-28 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-27 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-24 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-23 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-22 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-21 | B- | 2/5 | 1/5 | 2/5 | 5/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-20 | B- | 2/5 | 1/5 | 2/5 | 5/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-17 | B- | 2/5 | 1/5 | 2/5 | 5/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-16 | B- | 2/5 | 1/5 | 2/5 | 5/5 | 2/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Kodex Healthcare 266420.KS | 0.40% | 182.4K | 0.09% |
| 2 | Kodex KOSDAQ 150 229200.KS | 0.33% | 9.99M | 0.25% |
| 3 | SAMSUNG KODEX KOSDAQ150 LEVERAGE ETF 233740.KS | 0.10% | 2.29M | 0.64% |
| 4 | Samsung Kodex Fn Growth ETF 325010.KS | 0.05% | 48.6K | 0.30% |
| 5 | Kodex KRX300 292190.KS | 0.03% | 15.0K | 0.05% |
| 6 | iShares MSCI AC Far East ex-Japan Small Cap UCITS ETF ISFE.L | 0.02% | 16.7K | 0.74% |
| 7 | Avantis Emerging Markets Small Cap Equity ETF AVEE | 0.02% | 26.1K | 0.42% |
| 8 | State Street SPDR MSCI Emerging Markets Small Cap UCITS ETF EMSD.L | 0.02% | 128.2K | 0.55% |
| 9 | iShares MSCI Emerging Markets Small-Cap ETF EEMS | 0.02% | 62.6K | 0.72% |
| 10 | iShares MSCI EM Small Cap UCITS ETF IEMS.L | 0.02% | 53.9K | 0.74% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hyun-Ho Jung | Chief Executive Officer & Chairman | — | male |
| Ki-Hyuk Yang | Head of Laboratory, Senior MD & Director | — | male |
| Seung-Bum Park | Head of Production Division & Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 086900.KQ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
